Next 10 |
home / stock / nvzmf / nvzmf news
2023-05-09 23:17:21 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-04-26 21:11:04 ET Novozymes A/S (NVZMF) Q1 2023 Earnings Conference Call April 26, 2023, 03:00 ET Company Participants Tobias Bjorklund - Head of IR Ester Baiget - President & CEO Lars Green - EVP & CFO Amy Byrick - EVP, Strategy & Business T...
2023-04-26 03:17:15 ET Novozymes A/S press release ( OTCPK:NVZMF ): Q1 GAAP EPS of DKK 2.82. Revenue of DKK 4.62B (+5.7% Y/Y), delivers 5% organic sales growth, an EBIT-margin of 26.0% before special items, and ROIC including goodwill of 17.7% before special items. 2023 ou...
After the first quarter of 2023, Novozymes delivers stronger results than expected with 5% organic sales growth. The company confirms the 2023 outlook of 4-7% which is expected to be driven by pricing and volume growth. COPENHAGEN, Denmark – April 26, 2023. In the first three mon...
2023-04-08 02:16:45 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-03-21 10:19:23 ET Summary Exposure to large and growing markets should be supportive of Novozymes' long-term revenue growth. Enzymes may offer a more defendable market that supports higher margins than many specialty chemical market segments. Novozymes' valuation has decl...
2023-03-08 00:56:48 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further...
Novozymes A/S (NVZMF) Q4 2022 Earnings Conference Call January 26, 2023 3:00 AM ET Company Participants Tobias Bjorklund - Head of Investor Relations Ester Baiget - President and CEO Lars Green - Executive Vice President and CFO Tina Sejersgard Fano - Executive Vic...
The following slide deck was published by Novozymes A/S in conjunction with their 2022 Q4 earnings call. For further details see: Novozymes A/S 2022 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Novozymes A/S Company Name:
NVZMF Stock Symbol:
OTCMKTS Market:
After the first quarter of 2023, Novozymes delivers stronger results than expected with 5% organic sales growth. The company confirms the 2023 outlook of 4-7% which is expected to be driven by pricing and volume growth. COPENHAGEN, Denmark – April 26, 2023. In the first three mon...
Novozymes is delivering strong growth and earnings in a volatile market environment with 9% organic sales growth in 2022. This marks the highest organic sales growth in more than a decade, and Novozymes is confident about the 2023 outlook of 4-7%. COPENHAGEN, Denmark – January 26, ...
New York City, NY: May 25, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Enzyme Market in Global Industry: 2020 Research and New Innovations in Oil and Gas Sector. The prime objective of the report is to offer updates and information relate...